

### AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

**1-41 (Cancelled)**

**42. (Currently Amended)** The An isolated polypeptide of ~~Claim 39~~ having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);

(b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2) lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein the nucleic acid encoding said polypeptide is amplified in rectal tumors.

**43. (Currently Amended)** The isolated polypeptide of Claim 39 42 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);

(b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2) lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein the nucleic acid encoding said polypeptide is amplified in rectal tumors.

- 44. (Previously Presented)** An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2);
  - (b) the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2) lacking its associated signal peptide;
  - (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2);
  - (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide; or
  - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099.
- 45. (Previously Presented)** The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2).
- 46. (Previously Presented)** The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide.
- 47. (Previously Presented)** The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2).
- 48. (Previously Presented)** The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), lacking its associated signal peptide.
- 49. (Previously Presented)** The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099.
- 50. (Previously Presented)** A chimeric polypeptide comprising a polypeptide according to Claim 39 fused to a heterologous polypeptide.
- 51. (Previously Presented)** The chimeric polypeptide of Claim 50, wherein the heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.